52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Amneal Reports Q1 Adj Non-GAAP Earnings Per Share Of $0.20
Amneal Reports Fourth Quarter And Full Year 2020 Results
Amneal Pharmaceuticals Q3 Loss Per Share $0.06
Amneal Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the developing, manufacturing, marketing and distributing high-value generic and branded specialty pharmaceutical products across a broad array of dosage forms and therapeutic areas. It operates in three segments, which include Generics, Specialty and AvKARE. The Generics segment provides prescription pharmaceutical products. The Specialty Pharma is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders. AvKARE segment provides pharmaceuticals, medical and surgical products and services to governmental agencies. Its other pipeline includes 505(b)(2) drugs and complex generics.
Biotechnology & Drugs
400 Crossing Blvd Fl 3
Paul M. Meister
Independent Chairman of the Board
President, Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
Anastasios G. Konidaris
Chief Financial Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The U.S. Federal Trade Commission said on Monday it has filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER.
The U.S. Federal Trade Commission said on Monday it is filing a lawsuit against Endo Pharmaceuticals and Impax Laboratories which alleges a 2017 agreement eliminated competition between them for oxymorphone ER.
* AMNEAL LAUNCHES GENERIC FLUPHENAZINE FOLLOWING ANDA APPROVAL BY FDA
Impax Laboratories on Tuesday urged a federal appeals court to overturn the U.S. Federal Trade Commission's finding that it entered into an illegal pay-for-delay patent litigation settlement that delayed the release of a generic version of the opioid Opana ER.
* Q1 REVENUE $499 MILLION VERSUS REFINITIV IBES ESTIMATE OF $446.1 MILLION
* AMNEAL LAUNCHES GENERIC BUTRANS® FOLLOWING ANDA APPROVAL BY FDA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
A federal appeals court on Wednesday declined to reconsider a recent decision that dealt a setback to Amneal Pharmaceuticals Inc in its bid to launch a generic version of the Amgen Inc drug Sensipar.
* AMNEAL ACCELERATES DISTRIBUTION AND PRODUCTION OF HYDROXYCHLOROQUINE SULFATE TO MEET POTENTIAL NEEDS OF COVID-19 PATIENTS NATIONWIDE
* AMNEAL PHARMACEUTICALS APPOINTS TASOS KONIDARIS AS SENIOR VICE PRESIDENT, CHIEF FINANCIAL OFFICER
Shares of Amneal Pharmaceuticals Inc plunged 36% to an all-time low on Wednesday after the generic drugmaker cut its 2019 core earnings forecast due to supply uncertainties related to its epinephrine auto-injectors.
Amneal Pharmaceuticals Inc on Wednesday cut its core earnings forecast for the year, citing uncertainty in supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV's EpiPen.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.